Jan Garfinkle founded Arboretum Ventures in 2002 and is a Managing Director.
Jan leads the fund-raising effort at Arboretum and has raised over $450 million over four funds. At Arboretum, Jan’s investments focus on promising medical technologies that enable meaningful healthcare system savings. Jan has led more than a dozen investments and currently serves on the Board of Directors for Ebb Therapeutics, NeuMoDx, Cardiac Dimensions and Strata Oncology. Jan’s past investments have led to successful exits creating over $2 billion in enterprise value. These include HandyLab (acquired by Becton Dickinson in 2009), Esperion (IPO in 2013), CardioMEMS (acquired by St. Jude Medical in 2014) and NxThera (acquired by Boston Scientific in 2018).
Prior to founding Arboretum, Jan spent 20 years in entrepreneurial healthcare companies. She was Founder and President of Strategic Marketing Consultants, advising healthcare start-ups and major medical device companies. Prior to this, Jan held key management roles for two successful medical device start-ups, Advanced Cardiovascular Systems and Devices for Vascular Intervention. Each of these companies was acquired by Eli Lilly and became the foundation for Guidant Corporation. Earlier in her career, Jan was an engineer and product manager for Procter & Gamble.
Jan is a member of the Board of Directors and Executive Committee for the National Venture Capital Association (NVCA), and on the Board of Directors of the St. Joseph Mercy Regional Health System. Jan has been recognized as the 2015 Crain’s Newsmaker of the Year, and in 2016 as one of Crain’s Most Influential Women. Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.